CSF1R and pancreatic ductal adenocarcinoma: In another phase Ib/II study, patients with advanced pancreatic ductal carcinoma, colorectal cancer, or non-small cell lung cancer were treated with a CSF-1R monoclonal antibody plus anti-PD-1 therapy; however, minimal anti-tumor activity was observed [62].